Development and characterization of an oral dosage form containing Entacapone, Carbidopa, and L-dopa
Carregando...
Data
2014
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Entacapone is a catechol-o-methyltransferase (COMT) inhibitor used in association with
carbidopa and L-dopa in the treatment of Parkinson’s disease. The tablets containing
entacapone associated with carbidopa and L-dopa should also contain elements to promote its
bioavailability, since entacapone presents low solubility and low permeability. The objectives
of this study were the development and physicochemical characterization of tablets containing
an association of entacapone, carbidopa, and L-dopa using Stalevo® as a reference medication.
To achieve these goals, different batches of tablets were produced containing surfactants such
as sodium dodecyl sulfate and poloxamers 118 and 407 using the wet granulation method in a
high shear mixer. The tablet cores obtained were approved regarding the following
physicochemical properties: friability, hardness, disintegration, content of active ingredient,
and dissolution. The coated tablets containing poloxamer 407 presented dissolution profile
similar to the reference medication.
Descrição
Palavras-chave
Levodopa, Doença de Parkinson, Carbidopa, Entacapone, Poloxamer, Tecnologia farmacêutica, Levodopa, Parkinson disease, Carbidopa, Pharmaceutical Technology, Entacapone, Poloxamer
Citação
Rodovalho-Mitani, Luciana Ferreira Fonseca et al. Development and characterization of an oral dosage form containing Entacapone, Carbidopa, and L-dopa. Revista Brasileira de Farmácia, Rio de Janeiro, v. 95, n. 3, p. 796-813, 2014.